Viemed Healthcare, Inc.
VMD Healthcare Medical Devices
Viemed Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $270.3 million, up 20.5% from fiscal 2024. In the quarter to June 2026, revenue grew 23.9%, EPS fell 12.5%, free cash flow fell 18.2% and total debt rose 65.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow VMD
Viemed Healthcare, Inc. (VMD) EV/Sales
As of 16 October 2026, Viemed Healthcare, Inc. (VMD) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.9× (August 2025) to 5.2× (June 2020); the current reading is higher than 15% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.1× | (19.65%) |
| FY2024 | 1.3× | (19.35%) |
| FY2023 | 1.6× | (17.21%) |
| FY2022 | 2.0× | 26.45% |
| FY2021 | 1.6× | (25.86%) |
| FY2020 | 2.1× | (27.03%) |
| FY2019 | 2.9× | (18.18%) |
| FY2018 | 3.5× | 0.00% |
| FY2017 | 3.5× | 0.00% |
| FY2016 | 3.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.4× | 16.27% |
| Mar 2026 | 1.2× | 15.77% |
| Dec 2025 | 1.1× | (0.36%) |
| Sep 2025 | 1.1× | 0.07% |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OFIX ORTHOFIX MEDICAL INC. compare | 0.6× |
| VMD Viemed Healthcare, Inc. | 1.2× |
| RCEL Avita Medical Inc. compare | 1.3× |
| CERS Cerus Corporation compare | 1.8× |
| NPCE NeuroPace, Inc. compare | 4.2× |
| SI Shoulder Innovations, Inc. compare | 4.8× |
| CLPT ClearPoint Neuro, Inc. compare | 7.0× |
| SENS Senseonics Holdings, Inc. compare | 8.1× |
| CV CapsoVision, Inc. compare | 22.8× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)